R10MEDICINE

r10.life

R10MEDICINE is an innovative new community for aspiring physicians and physicians aimed at exploring new solutions to the growing problems in the medical profession and in healthcare. Any medical student, graduate, or physician from anywhere can join. Members have access to a myriad of programs, benefits, and opportunities found exclusively here.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

ITERATIVE SCOPES ACQUIRES CLINICAL RESEARCH STRATEGY GROUP AND PRECISION RESEARCH

Iterative Scopes | April 29, 2022

news image

On April 28, Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced that it acquired Clinical Research Strategy Group, LLC, and Precision Research. These two clinical trial optimization companies focus on streamlining and speeding the drug development process for inflammatory bowel disease (IBD). Through this acquisition, Iterative Scopes’ ties to the IBD clinical research community are deepened, and its knowledge of the end-to-end res...

Read More

Pharma Tech

XTALPI ANNOUNCES COLLABORATION WITH LILLY, USING AI + ROBOTICS TO UNCOVER FIRST-IN-CLASS THERAPEUTICS

PRNewswire | May 31, 2023

news image

Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company. The collaboration will leverage XtalPi's integrated AI capabilities and robotics platform to de novo design and deliver drug candidates for an undisclosed target. XtalPi has established itself as an industry leader in combining...

Read More

Pharmacy Market

ASTELLAS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 LONG-TERM SAFETY STUDY OF FEZOLINETANT IN MAINLAND CHINA

Astellas Pharma Inc. | September 05, 2022

news image

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. MOONLIGHT 3 is a 52-week single-arm Phase 3 clinical trial ...

Read More

Pharmacy Market

NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR 0.9% SODIUM CHLORIDE INJECTION

businesswire | August 31, 2023

news image

Nexus Pharmaceuticals LLC announced it has received U.S. Food and Drug Administration (FDA) approval for 0.9% Sodium Chloride Injection, USP in 10mL and 20mL Single-Dose Vials. “This product is part of an expanding portfolio of products that address critical healthcare challenges,” said Omair Ahmed, Chief Operating Officer. “Sodium Chloride Injection is used to treat patients every day in every hospital in the United States. We are grateful to be able to bolste...

Read More
news image

Business Insights

ITERATIVE SCOPES ACQUIRES CLINICAL RESEARCH STRATEGY GROUP AND PRECISION RESEARCH

Iterative Scopes | April 29, 2022

On April 28, Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced that it acquired Clinical Research Strategy Group, LLC, and Precision Research. These two clinical trial optimization companies focus on streamlining and speeding the drug development process for inflammatory bowel disease (IBD). Through this acquisition, Iterative Scopes’ ties to the IBD clinical research community are deepened, and its knowledge of the end-to-end res...

Read More
news image

Pharma Tech

XTALPI ANNOUNCES COLLABORATION WITH LILLY, USING AI + ROBOTICS TO UNCOVER FIRST-IN-CLASS THERAPEUTICS

PRNewswire | May 31, 2023

Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company. The collaboration will leverage XtalPi's integrated AI capabilities and robotics platform to de novo design and deliver drug candidates for an undisclosed target. XtalPi has established itself as an industry leader in combining...

Read More
news image

Pharmacy Market

ASTELLAS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 LONG-TERM SAFETY STUDY OF FEZOLINETANT IN MAINLAND CHINA

Astellas Pharma Inc. | September 05, 2022

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. MOONLIGHT 3 is a 52-week single-arm Phase 3 clinical trial ...

Read More
news image

Pharmacy Market

NEXUS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR 0.9% SODIUM CHLORIDE INJECTION

businesswire | August 31, 2023

Nexus Pharmaceuticals LLC announced it has received U.S. Food and Drug Administration (FDA) approval for 0.9% Sodium Chloride Injection, USP in 10mL and 20mL Single-Dose Vials. “This product is part of an expanding portfolio of products that address critical healthcare challenges,” said Omair Ahmed, Chief Operating Officer. “Sodium Chloride Injection is used to treat patients every day in every hospital in the United States. We are grateful to be able to bolste...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us